SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular len... SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was incorporated in 2019 and is based in Aliso Viejo, California. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.16 | -5.8 | 20 | 20.27 | 17.6 | 47982 | 18.82982122 | CS |
| 4 | -6.93 | -26.8917345751 | 25.77 | 26.03 | 17.6 | 48264 | 21.03496381 | CS |
| 12 | -7.53 | -28.5551763367 | 26.37 | 28.2 | 17.6 | 88379 | 24.01573526 | CS |
| 26 | -6.41 | -25.3861386139 | 25.25 | 30.56 | 17.6 | 94422 | 25.21360051 | CS |
| 52 | -6.41 | -25.3861386139 | 25.25 | 30.56 | 17.6 | 94422 | 25.21360051 | CS |
| 156 | -6.41 | -25.3861386139 | 25.25 | 30.56 | 17.6 | 94422 | 25.21360051 | CS |
| 260 | -6.41 | -25.3861386139 | 25.25 | 30.56 | 17.6 | 94422 | 25.21360051 | CS |
bobby1151
2分前
bobby1151
2分前
jimr1717
3分前
work-n-hard
5分前
Infinitygold
6分前
JamesF1
7分前
brooktrail1933
7分前
raiderz
8分前
TightCoil
8分前
mattdc
10分前
Large Green
10分前
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。